After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Kyle LaHucik

Senior Reporter

After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

AbbVie pens another T cell engager deal, this time with Xilio

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

Odyssey underwent layoffs; GSK to move vaccine R&D site to Cambridge

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Odyssey un­der­went lay­offs; GSK to move vac­cine R&D site to Cam­bridge

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

AbbVie pens another T cell engager deal, this time with Xilio

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

Odyssey underwent layoffs; GSK to move vaccine R&D site to Cambridge

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers